Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2015 Jun;232(12):2061-70.
doi: 10.1007/s00213-014-3839-0. Epub 2015 Jan 11.

A randomized, double-blind, duloxetine-referenced study comparing efficacy and tolerability of 2 fixed doses of vortioxetine in the acute treatment of adults with MDD

Atul R Mahableshwarkar  1 , Paula L Jacobsen, Yinzhong Chen, Michael Serenko, Madhukar H Trivedi
Affiliations
Randomized Controlled Trial

A randomized, double-blind, duloxetine-referenced study comparing efficacy and tolerability of 2 fixed doses of vortioxetine in the acute treatment of adults with MDD

Atul R Mahableshwarkar et al. Psychopharmacology (Berl). 2015 Jun.

Abstract

Rationale: Vortioxetine has reduced depressive symptoms in adults with major depressive disorder (MDD) in multiple clinical trials.

Objectives: The aim of this study is to evaluate the efficacy, safety, and tolerability of vortioxetine 15 and 20 mg vs placebo in adults with MDD.

Methods: Patients were randomized 1:1:1:1 to vortioxetine 15 mg, vortioxetine 20 mg, duloxetine 60 mg (active reference), or placebo. The primary efficacy endpoint was mean change in Montgomery-Åsberg Depression Rating Scale (MADRS) total score at week 8 (MMRM). Safety/tolerability assessments included physical examinations, vital signs, laboratory evaluations, electrocardiograms, adverse events (AEs), Columbia-Suicide Severity Rating Scale, Arizona Sexual Experiences Scale, and Discontinuation-Emergent Signs and Symptoms checklist.

Results: Six hundred and fourteen patients were randomized. Mean changes in MADRS scores were -12.83 (±0.834), -14.30 (±0.890), -15.57 (±0.880), and -16.90 (±0.884) for placebo, vortioxetine 15 mg (P = .224), vortioxetine 20 mg (P = .023), and duloxetine 60 mg (P < .001) (P vs placebo), respectively. AEs reported by ≥5 % of vortioxetine patients included nausea, headache, diarrhea, dizziness, dry mouth, constipation, vomiting, insomnia, fatigue, and upper respiratory infection. Treatment-emergent sexual dysfunction, suicidal ideation or behavior, and discontinuation symptoms were not significantly different between vortioxetine and placebo.

Conclusions: Vortioxetine 20 mg significantly reduced MADRS total scores after 8 weeks of treatment. Both vortioxetine doses were well tolerated.

Clinical trial registration: ClinicalTrials.gov identifier NCT01153009; www.clinicaltrials.gov/ .

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Patient disposition.aAll randomized patients who received ≥1 dose of double-blind study medication; bAll randomized patients who received ≥1 dose of double-blind study medication and had ≥1 valid post-baseline efficacy assessment; cAll patients in the full analysis set who had no major protocol violations
Fig. 2
Fig. 2
Least-squares change from baseline in Montgomery–Åsberg Depression Rating Scale total score by visit (full analysis set; mixed model for repeated measures). *Nominal P < .050; **Nominal P < .010; ***Nominal P < .001 vs placebo; †P < .025
See this image and copyright information in PMC

References

    1. Alvarez E, Perez V, Dragheim M, Loft H, Artigas F. A double-blind, randomized, placebo-controlled, active reference study of Lu AA21004 in patients with major depressive disorder. Int J Neuropsychopharmacol. 2012;15:589–600. doi: 10.1017/S1461145711001027. - DOI - PMC - PubMed
    1. Baldwin DS, Hansen T, Florea I. Vortioxetine (Lu AA21004) in the long-term open-label treatment of major depressive disorder. Curr Med Res Opin. 2012;28:1717–1724. doi: 10.1185/03007995.2012.725035. - DOI - PubMed
    1. Baldwin DS, Loft H, Dragheim M. A randomised, double-blind, placebo controlled, duloxetine-referenced, fixed-dose study of three dosages of Lu AA21004 in acute treatment of major depressive disorder (MDD) Eur Neuropsychopharmacol. 2012;22:482–491. doi: 10.1016/j.euroneuro.2011.11.008. - DOI - PubMed
    1. Bang-Andersen B, Ruhland T, Jørgensen M, Smith G, Frederiksen K, Jensen KG, Zhnog H, Nielsen SM, Hogg S, Mørk A, Stensbøl TB. Discovery of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine (Lu AA21004): a novel multimodal compound for the treatment of major depressive disorder. J Med Chem. 2011;54:3206–3221. doi: 10.1021/jm101459g. - DOI - PubMed
    1. Boulenger JP, Loft H, Florea I. A randomized clinical study of Lu AA21004 in the prevention of relapse in patients with major depressive disorder. J Psychopharmacol. 2012;26:1408–1416. doi: 10.1177/0269881112441866. - DOI - PubMed

Publication types

MeSH terms

Associated data